1 21 4

Shareholder Tools

Home Investor Relations

Investor Relations

  1. Chart
  2. Quote
Stock price graph
+ 0.20
Day High:
Day Low:
1:00 PM ET on Nov 27, 2015

Delayed at least 20 minutes.
Provided by eSignal.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. MacroGenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. The combination of MacroGenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

Corporate Fact Sheet

Corporate Fact Sheet

PDF  Corporate Fact Sheet

View all »   RSSRecent Releases

Nov 7, 2015
Data from MacroGenics' Ongoing Phase 1 Study of Enoblituzumab (MGA271) Presented at 30th Annual SITC Meeting 2015

Nov 5, 2015
Publication in PLOS Pathogens Shows the Potential of DART® Molecules for HIV Reservoir Elimination Strategy